JS001sc

· Shanghai Junshi Bioscience Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for JS001sc, covering 2025-08-28 to 2025-08-28. Get the full timeline:

Most recent: Clinical Trial Update: JS001sc or JS001 Plus Chemotherapy is Indicated for Relapsed or Metastatic First-Line Non-Squamous Non Small Cell Lung Cancer（NSCLC） [Phase 3]

See pricing